Holen Sie sich die Stockscreener-App
3.12
6.87%
-0.23
Handel nachbörslich:
3.12
Schlusskurs vom Vortag:
$3.35
Offen:
$3.2
24-Stunden-Volumen:
59,282
Relative Volume:
0.02
Marktkapitalisierung:
$18.61M
Einnahmen:
$34.75M
Nettoeinkommen (Verlust:
$-24.76M
KGV:
-0.26
EPS:
-12
Netto-Cashflow:
$-50.91M
1W Leistung:
-2.50%
1M Leistung:
+9.47%
6M Leistung:
-81.99%
1J Leistung:
-92.79%
1-Tages-Spanne:
$3.0509
$3.2899
1-Wochen-Bereich:
$2.72
$3.45
52-Wochen-Spanne:
$2.15
$98.75
Allurion Technologies Inc Stock (ALUR) Company Profile
Firmenname
Allurion Technologies Inc
Sektor
Branche
Telefon
508-647-4000
Adresse
11 HURON DR STE 200, NATICK
Vergleichen Sie ALUR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALUR
Allurion Technologies Inc
|
3.12 | 18.61M | 34.75M | -24.76M | -50.91M | -12.00 |
|
ABT
Abbott Laboratories
|
131.63 | 228.29B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
98.50 | 145.69B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
368.15 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
87.89 | 112.70B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.98 | 42.75B | 5.72B | 4.17B | 259.90M | 6.97 |
Allurion Technologies Inc Stock (ALUR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-10-02 | Eingeleitet | TD Cowen | Buy |
| 2024-09-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-02-09 | Eingeleitet | Jefferies | Buy |
Allurion Technologies Inc Aktie (ALUR) Neueste Nachrichten
Allurion reschedules special stockholders meeting to April 10 By Investing.com - Investing.com UK
Allurion Gives Shareholders More Time: Key Meeting Rescheduled to April 10 - Stock Titan
Allurion Technologies CEO Gaur Shantanu acquires $26,800 in stock By Investing.com - Investing.com Canada
Allurion Technologies CEO Gaur Shantanu acquires $26,800 in stock - Investing.com India
Allurion Technologies CEO Acquires 8,000 Shares - TradingView
12 Consumer Discretionary Stocks Moving In Monday's After-Market Session - Benzinga
Allurion Technologies’ Earnings Call: Growth Amid Challenges - TipRanks
Analysts Offer Insights on Healthcare Companies: Allurion Technologies (ALUR), Perspective Therapeutics (CATX) and Nkarta (NKTX) - The Globe and Mail
Chardan holds Allurion stock at Neutral with a $2.50 target By Investing.com - Investing.com South Africa
Chardan holds Allurion stock at Neutral with a $2.50 target - Investing.com
Allurion Technologies Inc (ALUR) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ... By GuruFocus - Investing.com Canada
Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - BioSpace
TD Cowen Cuts Allurion Technologies' Price Target to $6 From $16, Buy Rating Maintained - MarketScreener
Allurion Technologies, Inc. (ALUR) Reports Q4 Loss, Lags Revenue Estimates - MSN
Earnings call transcript: Allurion Technologies’ Q4 2024 shows revenue drop, strategic shifts By Investing.com - Investing.com South Africa
Earnings call transcript: Allurion Technologies’ Q4 2024 shows revenue drop, strategic shifts - Investing.com
Allurion Technologies Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ALLURION TECHNOLOGIES Earnings Results: $ALUR Reports Quarterly Earnings - Nasdaq
Earnings Scheduled For March 26, 2025 - Benzinga
Allurion Technologies Reports 2024 Financial Results and Outlook - TipRanks
What To Expect From Allurion Technologies Inc (ALUR) Q4 2024 Earnings - Yahoo Finance
Allurion surges on weight loss data from gastric balloon, GLP-1 combo treatment - MSN
Gold Down Over 1%; Micron Technology Shares Fall After Q2 Earnings - Benzinga
Allurion Stock Soars on Promising GLP-1 Combo Results - Wall Street Pit
Promising Potential of Allurion Technologies’ Innovative Approach Supports Buy Rating - TipRanks
Why Ouster Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga
US Stocks Likely To Open Lower, But 'Economic Conditions Don't Signal A Downturn,' Say Analysts As They Expect 'Resilient Earnings' To Lift EquitiesAllurion Technologies (NYSE:ALUR), Accenture (NYSE:ACN) - Benzinga
Allurion reports weight loss and muscle gain with new therapy By Investing.com - Investing.com South Africa
Allurion Technologies Reports Positive Ballon Combination Study Results; Shares Jump - MarketScreener
Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence - BioSpace
12 Consumer Discretionary Stocks Moving In Thursday's After-Market Session - Benzinga
Allurion reports weight loss and muscle gain with new therapy - Investing.com India
Revolutionary Weight Loss Results: Allurion Balloon Plus Low-Dose GLP-1 Shows 20% Weight Loss, Preserves Muscle - StockTitan
Analysts Offer Insights on Healthcare Companies: Allurion Technologies (ALUR) and Esperion (ESPR) - The Globe and Mail
ALLURION TECHNOLOGIES Earnings Preview: Recent $ALUR Insider Trading, Hedge Fund Activity, and More - Nasdaq
Allurion’s Next-Generation Weight Loss Device Earns New Patents - MPO-mag
Allurion Technologies (ALUR) Projected to Post Quarterly Earnings on Thursday - Defense World
Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025 - The Joplin Globe
Q1 EPS Forecast for Allurion Technologies Cut by Analyst - Defense World
Allurion Technologies price target lowered to $16 on split-adjusted basis - TipRanks
Allurion Balloon Reintroduced in France - MPO-mag
Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity - BioSpace
Allurion Technologies announces issuance of new patents on weight loss device - TipRanks
Allurion Announces Notification Of Issuance Of New U.S. Patents On Next-Generation Weight Loss Device For The Treatment Of Obesity - Marketscreener.com
Allurion to Participate in Upcoming Investor Conferences - 01Net
Allurion to Participate in Upcoming Investor Conferences -February 25, 2025 at 04:06 pm EST - Marketscreener.com
Can Allurion's Anti-Obesity Strategy Impress Investors at Major Healthcare Conferences? - StockTitan
ALURALLURION TECHNOLOGIES INC Latest Stock News & Market Updates - StockTitan
Allurion to raise $6.1 million in direct offering and private placement - MSN
Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline - BioSpace
Can Allurion's Balloon-GLP-1 Combo Reshape Weight Loss Treatment? $6.1M Bet Says Yes - StockTitan
Finanzdaten der Allurion Technologies Inc-Aktie (ALUR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.71%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):